Clinical Trials Logo
  1. Home
  2. Primary Sjögren's Syndrome
  3. NCT04212572
  4. Details
NCT04212572 Clinical Trial

Ultrasound Abnormalities of the Salivary Glands in Primary Sjögren's Syndrome According to the Duration of the Disease

Primary sjögren's Syndrome Clinical Trial

— MASAÏ  

Official title:
Ultrasound Abnormalities of the Salivary Glands in Primary Sjögren's Syndrome

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT04212572
Other study ID # MASAI (29BRC19.0103)
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 20, 2019
Est. completion date May 20, 2020

Study information
Verified date December 2019
Source University Hospital, Brest
Contact Valerie DEVAUCHELLE
Phone 2 98 34 72 64
Email valerie.devauchelle-pensec@chu-brest.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Salivary gland ultrasonography is identified as a valuable diagnostic tool and potential criteria item for disease classification of sjögren's syndrome and evaluate evolution of parenchyma.

The investigators have to include 242 patients. The objective is to evaluate the modification of ultrasonographic abnormalities according to disease in primary Sjögren syndrome.

Recruitment information / eligibility
Status Recruiting
Enrollment 242
Est. completion date May 20, 2020
Est. primary completion date May 20, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male or female patient = 18 years

- Primary sjögren syndrome according of age to 2002 or 2016 classification criteria

Exclusion Criteria:

- Secondary sjögren syndrome

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
France CHRU de Brest Brest
France CHU de LILLE Lille
France CHU de MONTEPELLIER Montpellier

Sponsors (1)
Lead Sponsor Collaborator
University Hospital, Brest

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Presence or absence of parenchymal abdnormalities. Presence or absence of parenchymal abdnormalities. Scored following a standardized fill and according to disease duration inclusion
Secondary Parenchymal abnormalities according to disease activity Ultrasonography parenchymal abnormalities of salivary gland inclusion
See also
  Status Clinical Trial Phase
Recruiting NCT03040583 - The ASSESS National Multi-center Prospective Cohort
Completed NCT01989819 - Primary Sjögren Syndrome
Completed NCT02291029 - Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome Phase 2
Terminated NCT02610543 - UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome Phase 2
Not yet recruiting NCT04975087 - The Profile of Fatigue and Discomfort - Sicca Symptoms Inventory
Recruiting NCT06203457 - Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome Phase 2
Completed NCT04078386 - A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome Phase 2
Recruiting NCT05087589 - Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's Syndrome Phase 2
Completed NCT02149420 - PD of VAY736 in Patients With Primary Sjögren's Syndrome Phase 2
Recruiting NCT04858464 - Reliability, Validity of the Turkish Version of the Primary Sjögren Syndrome Quality of Life (PSS-QoL) Questionnaire
Recruiting NCT03003572 - Autoreactive Anti-Ro/SSA IgE To Determine Primary SjögRen's Syndrome's Disease Activity
Completed NCT00632866 - Hydroxychloroquine Versus Placebo in Primary Sjögren's Syndrome Phase 3
Completed NCT02334306 - A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome Phase 2
Completed NCT02775916 - Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome Phase 2
Completed NCT02464319 - A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome Phase 2
Terminated NCT01552681 - Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome Phase 2
Completed NCT04186871 - Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis Phase 2
Completed NCT00426543 - Effect of B-cell Depletion in Patients With Primary Sjögren's Syndrome Phase 2
Recruiting NCT04981145 - The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome Phase 4
Completed NCT03627065 - A Study of INCB050465 in Primary Sjögren's Syndrome Phase 2